2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
74
Hodgkin Disease
56
Lymphoma
22
Sarcoma
13
Neoplasm Metastasis
11
Leiomyosarcoma
8
Uveal Melanoma
7
Neoplasms
7
Skin Neoplasms
6
Neuroblastoma
4
Sarcoma, Synovial
3
Recurrence
3
Solitary Fibrous Tumors
2
Sarcoma, Alveolar Soft Part
2
Hematologic Diseases
2
HIV Infections
2
Thyroid Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Melanoma, Cutaneous Malignant
1
Melanoma Neoplasms
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Dacarbazine
×
Clear all
NCT00070642
2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2
Completed
184 enrolled